{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ADMET", "DFT", "VEGFR-2 inhibitors", "in vitro antiproliferative", "molecular docking", "molecular dynamics simulations", "pyridine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36431818", "DateCompleted": {"Year": "2022", "Month": "11", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "11", "Day": "09"}], "Language": ["eng"], "ELocationID": ["7719", "10.3390/molecules27227719"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "22", "PubDate": {"Year": "2022", "Month": "Nov", "Day": "09"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "(<i>E</i>)-<i>N</i>-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth Factor Receptor-2: Synthesis, Computational, and Anticancer Studies.", "Abstract": {"AbstractText": ["(<i>E</i>)-<i>N</i>-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide (compound <b>10</b>) was designed as an antiangiogenic VEGFR-2 inhibitor with the essential pharmacophoric structural properties to interact with the catalytic pocket of VEGFR-2. The designed derivative was synthesized, and its structure was confirmed through Ms, elemental, <sup>1</sup>H, and <sup>13</sup>C spectral data. The potentiality of the designed pyridine derivative to bind with and inhibit the vascular endothelial growth factor receptor-2 (VEGFR-2) enzyme was indicated by molecular docking assessments. In addition, six molecular dynamic (MD) experiments proved its correct binding with VEGFR-2 over 100 ns. Additionally, the molecular mechanics energies, combined with the generalized born and surface area (MM-GBSA) analysis, identified the precise binding with optimum energy. To explore the stability and reactivity of the designed pyridine derivative, density functional theory (DFT) calculations, including electrostatic potential maps and total electron density, were carried out. Additionally, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis demonstrated its general likeness and its safety. The designed compound was synthesized to evaluate its effects against VEGFR-2 protein, cancer, and normal cells. The in vitro results were concordant with the in silico results, because the new pyridine derivative (compound <b>10</b>) displayed VEGFR-2 inhibition with an IC<sub>50</sub> value of 65 nM and displayed potent cytotoxic properties against hepatic (HepG2) and breast (MCF-7) cancer cell lines with IC<sub>50</sub> values of 21.00 and 26.10 \u03bcM, respectively; additionally, it exhibited high selectivity indices against the normal cell lines (W-38) of 1.55 and 1.25, respectively. The obtained results present compound <b>10</b> as a new lead VEGFR-2 inhibitor for further biological investigation and chemical modifications."]}, "AuthorList": [{"Identifier": ["0000-0003-3709-1930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0003-0893-6703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0003-0637-4268"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Gobaara", "ForeName": "Ibraheem M M", "Initials": "IMM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia."}], "LastName": "Al-Ghulikah", "ForeName": "Hanan A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "GrantList": [{"GrantID": "PNURSP2022R95", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}, {"RegistryNumber": "25X51I8RD4", "NameOfSubstance": "Niacinamide"}, {"RegistryNumber": "0", "NameOfSubstance": "Vascular Endothelial Growth Factor A"}], "MeshHeadingList": [{"QualifierName": ["metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Niacinamide"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor A"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Hassan G.S. Synthesis and antitumor activity of certain new thiazolo [2, 3-b] quinazoline and thiazolo [3, 2-a] pyrimidine analogs. Med. Chem. Res. 2014;23:388\u2013401. doi: 10.1007/s00044-013-0649-6.", "ArticleIdList": ["10.1007/s00044-013-0649-6"]}, {"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "DeVita V.T., Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u20138653. doi: 10.1158/0008-5472.CAN-07-6611.", "ArticleIdList": ["10.1158/0008-5472.CAN-07-6611", "18974103"]}, {"Citation": "Atkins J.H., Gershell L.J. Selective anticancer drugs. Nat. Rev. Cancer. 2002;2:645\u2013646. doi: 10.1038/nrc900.", "ArticleIdList": ["10.1038/nrc900", "12120255"]}, {"Citation": "Alsaif N.A., Taghour M.S., Alanazi M.M., Obaidullah A.J., Alanazi W.A., Alasmari A., Albassam H., Dahab M.A., Mahdy H.A. Identification of new [1, 2, 4] triazolo [4, 3-a] quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorg. Med. Chem. 2021;46:116384. doi: 10.1016/j.bmc.2021.116384.", "ArticleIdList": ["10.1016/j.bmc.2021.116384", "34479065"]}, {"Citation": "Elrazaz E.Z., Serya R.A., Ismail N.S., Albohy A., Abou El Ella D.A., Abouzid K.A. Discovery of potent thieno [2, 3-d] pyrimidine VEGFR-2 inhibitors: Design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Bioorg. Chem. 2021;113:105019. doi: 10.1016/j.bioorg.2021.105019.", "ArticleIdList": ["10.1016/j.bioorg.2021.105019", "34091286"]}, {"Citation": "Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006;2:213. doi: 10.2147/vhrm.2006.2.3.213.", "ArticleIdList": ["10.2147/vhrm.2006.2.3.213", "PMC1993983", "17326328"]}, {"Citation": "Roskoski R., Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007;62:179\u2013213. doi: 10.1016/j.critrevonc.2007.01.006.", "ArticleIdList": ["10.1016/j.critrevonc.2007.01.006", "17324579"]}, {"Citation": "Modi S.J., Kulkarni V.M. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: Medicinal chemistry perspective. Med. Drug Discov. 2019;2:100009. doi: 10.1016/j.medidd.2019.100009.", "ArticleIdList": ["10.1016/j.medidd.2019.100009"]}, {"Citation": "Fontanella C., Ongaro E., Bolzonello S., Guardascione M., Fasola G., Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann. Transl. Med. 2014;2:12.", "ArticleIdList": ["PMC4260048", "25568876"]}, {"Citation": "El-Metwally S.A., Abou-El-Regal M.M., Eissa I.H., Mehany A.B., Mahdy H.A., Elkady H., Elwan A., Elkaeed E.B. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg. Chem. 2021;112:104947. doi: 10.1016/j.bioorg.2021.104947.", "ArticleIdList": ["10.1016/j.bioorg.2021.104947", "33964580"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., Doghish A.S., Ismail A., Taghour M.S., Elkaeed E.B., Eissa I.H., Dahab M.A., Mahdy H.A. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:397\u2013410. doi: 10.1080/14756366.2021.2015343.", "ArticleIdList": ["10.1080/14756366.2021.2015343", "PMC8725875", "34961427"]}, {"Citation": "Saleh N.M., Abdel-Rahman A.A.H., Omar A.M., Khalifa M.M., El-Adl K. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking. Arch. Der Pharm. 2021;354:2100085. doi: 10.1002/ardp.202100085.", "ArticleIdList": ["10.1002/ardp.202100085", "33948983"]}, {"Citation": "Mahdy H.A., Ibrahim M.K., Metwaly A.M., Belal A., Mehany A.B., El-Gamal K.M., El-Sharkawy A., Elhendawy M.A., Radwan M.M., Elsohly M.A. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg. Chem. 2020;94:103422. doi: 10.1016/j.bioorg.2019.103422.", "ArticleIdList": ["10.1016/j.bioorg.2019.103422", "31812261"]}, {"Citation": "Alanazi M.M., Elkady H., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Alanazi M.M., Alharbi M.A., Eissa I.H., Dahab M.A. New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv. 2021;11:30315\u201330328. doi: 10.1039/D1RA05925D.", "ArticleIdList": ["10.1039/D1RA05925D", "PMC9044819", "35493991"]}, {"Citation": "El-Adl K., El-Helby A.-G.A., Ayyad R.R., Mahdy H.A., Khalifa M.M., Elnagar H.A., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4 (3H)-ones as potential VEGFR-2 inhibitors. Bioorg. Med. Chem. 2021;29:115872. doi: 10.1016/j.bmc.2020.115872.", "ArticleIdList": ["10.1016/j.bmc.2020.115872", "33214036"]}, {"Citation": "Parmar D.R., Soni J.Y., Guduru R., Rayani R.H., Kusurkar R.V., Vala A.G., Talukdar S.N., Eissa I.H., Metwaly A.M., Khalil A. Discovery of new anticancer thiourea-azetidine hybrids: Design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg. Chem. 2021;115:105206. doi: 10.1016/j.bioorg.2021.105206.", "ArticleIdList": ["10.1016/j.bioorg.2021.105206", "34339975"]}, {"Citation": "Abdelgawad M.A., El-Adl K., El-Hddad S.S., Elhady M.M., Saleh N.M., Khalifa M.M., Khedr F., Alswah M., Nayl A.A., Ghoneim M.M. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2, 4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPAR\u03b3 Agonists. Pharmaceuticals. 2022;15:226. doi: 10.3390/ph15020226.", "ArticleIdList": ["10.3390/ph15020226", "PMC8880361", "35215339"]}, {"Citation": "El-Adl K., Sakr H.M., Yousef R.G., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., Eissa I.H. Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorg. Chem. 2021;114:105105. doi: 10.1016/j.bioorg.2021.105105.", "ArticleIdList": ["10.1016/j.bioorg.2021.105105", "34175720"]}, {"Citation": "Alanazi M.M., Mahdy H.A., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Al-Mehizia A.A., Alsubaie S.M., Dahab M.A., Eissa I.H. New bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2032, 4\u2032-c] quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Bioorg. Chem. 2021;112:104949. doi: 10.1016/j.bioorg.2021.104949.", "ArticleIdList": ["10.1016/j.bioorg.2021.104949", "34023640"]}, {"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Alasmari A.F., Albassam H., Elkady H., Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:1760\u20131782. doi: 10.1080/14756366.2021.1956488.", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., Elkady H., Alsfouk A.A., Ashour M.L., El Hassab M.A., Abou-Seri S.M., Metwaly A.M. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. Int. J. Mol. Sci. 2022;23:6912. doi: 10.3390/ijms23136912.", "ArticleIdList": ["10.3390/ijms23136912", "PMC9266348", "35805916"]}, {"Citation": "Elkaeed E.B., Eissa I.H., Elkady H., Abdelalim A., Alqaisi A.M., Alsfouk A.A., Elwan A., Metwaly A.M. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Int. J. Mol. Sci. 2022;23:8407. doi: 10.3390/ijms23158407.", "ArticleIdList": ["10.3390/ijms23158407", "PMC9369012", "35955547"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules. 2022;27:5859. doi: 10.3390/molecules27185859.", "ArticleIdList": ["10.3390/molecules27185859", "PMC9500845", "36144596"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., El-Deeb N.M., Kenawy A.M., Elkaeed E.B., Alsfouk A.A., Alesawy M.S., Metwaly A.M., Eissa I.H. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:1903\u20131917. doi: 10.1080/14756366.2022.2085693.", "ArticleIdList": ["10.1080/14756366.2022.2085693", "PMC9272924", "35801403"]}, {"Citation": "Adnane L., Trail P.A., Taylor I., Wilhelm S.M. Sorafenib (BAY 43-9006, Nexavar\u00ae), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597\u2013612.", "ArticleIdList": ["16757355"]}, {"Citation": "De Luca A., Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs Investig. Drugs J. 2010;13:636\u2013645.", "ArticleIdList": ["20799147"]}, {"Citation": "Yousef R.G., Eldehna W.M., Elwan A., Abdelaziz A.S., Mehany A., Gobaara I.M., Alsfouk B.A., Elkaeed E.B., Metwaly A.M., Eissa I. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2. Molecules. 2022;27:4079. doi: 10.3390/molecules27134079.", "ArticleIdList": ["10.3390/molecules27134079", "PMC9268560", "35807326"]}, {"Citation": "Yousef R.G., Ibrahim A., Khalifa M.M., Eldehna W.M., Gobaara I.M., Mehany A.B., Elkaeed E.B., Alsfouk A.A., Metwaly A.M., Eissa I.H. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: Virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J. Enzym. Inhib. Med. Chem. 2022;37:1389\u20131403. doi: 10.1080/14756366.2022.2070744.", "ArticleIdList": ["10.1080/14756366.2022.2070744", "PMC9116259", "35577416"]}, {"Citation": "Alanazi M.M., Elkady H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Al-Hossaini A.M., Alharbi M.A., Eissa I.H., Dahab M.A. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study. J. Mol. Struct. 2021;1253:132220. doi: 10.1016/j.molstruc.2021.132220.", "ArticleIdList": ["10.1016/j.molstruc.2021.132220"]}, {"Citation": "Alsaif N.A., Dahab M.A., Alanazi M.M., Obaidullah A.J., Al-Mehizia A.A., Alanazi M.M., Aldawas S., Mahdy H.A., Elkady H. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Bioorg. Chem. 2021;110:104807. doi: 10.1016/j.bioorg.2021.104807.", "ArticleIdList": ["10.1016/j.bioorg.2021.104807", "33721808"]}, {"Citation": "Elwan A., Abdallah A.E., Mahdy H.A., Dahab M.A., Taghour M.S., Elkaeed E.B., Mehany A.B., Nabeeh A., Adel M., Alsfouk A.A. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules. 2022;27:5047. doi: 10.3390/molecules27155047.", "ArticleIdList": ["10.3390/molecules27155047", "PMC9370530", "35956997"]}, {"Citation": "Belal A., Abdel Gawad N.M., Mehany A.B., Abourehab M.A., Elkady H., Al-Karmalawy A.A., Ismael A.S. Design, synthesis and molecular docking of new fused 1 H-pyrroles, pyrrolo [3, 2-d] pyrimidines and pyrrolo [3, 2-e][1, 4] diazepine derivatives as potent EGFR/CDK2 inhibitors. J. Enzym. Inhib. Med. Chem. 2022;37:1884\u20131902. doi: 10.1080/14756366.2022.2096019.", "ArticleIdList": ["10.1080/14756366.2022.2096019", "PMC9272933", "35801486"]}, {"Citation": "Abdallah A.E., Alesawy M.S., Eissa S.I., El-Fakharany E.M., Kalaba M.H., Sharaf M.H., Shama N.M.A., Mahmoud S.H., Mostafa A., Al-Karmalawy A.A. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: Molecular modeling and in vitro antiviral screening. New J. Chem. 2021;45:16557\u201316571. doi: 10.1039/D1NJ02710G.", "ArticleIdList": ["10.1039/D1NJ02710G"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M., Alsfouk B.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules. 2022;27:4606. doi: 10.3390/molecules27144606.", "ArticleIdList": ["10.3390/molecules27144606", "PMC9317904", "35889478"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches. Processes. 2022;10:1391. doi: 10.3390/pr10071391.", "ArticleIdList": ["10.3390/pr10071391"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Mehany A.B., Alsfouk B.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl) naphthalene-2-ol derivative. J. Biomol. Struct. Dyn. 2022;2022:1\u201316. doi: 10.1080/07391102.2022.2127907.", "ArticleIdList": ["10.1080/07391102.2022.2127907", "36184591"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., El-Deeb N., Kenawy A.M., Elkaeed E.B., Alsfouk B.A., Alesawy M.S., Husein D.Z., Metwaly A.M. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway. PLoS ONE. 2022;17:e0272362. doi: 10.1371/journal.pone.0272362.", "ArticleIdList": ["10.1371/journal.pone.0272362", "PMC9506633", "36149902"]}, {"Citation": "Wang T., Husein D.Z. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2022;2022:1\u201328. doi: 10.1007/s11356-022-20050-2.", "ArticleIdList": ["10.1007/s11356-022-20050-2", "35460480"]}, {"Citation": "Husein D.Z., Hassanien R., Khamis M. Cadmium oxide nanoparticles/graphene composite: Synthesis, theoretical insights into reactivity and adsorption study. RSC Adv. 2021;11:27027\u201327041. doi: 10.1039/D1RA04754J.", "ArticleIdList": ["10.1039/D1RA04754J", "PMC9037664", "35480026"]}, {"Citation": "Ferreira L.L., Andricopulo A.D. ADMET modeling approaches in drug discovery. Drug Discov. Today. 2019;24:1157\u20131165. doi: 10.1016/j.drudis.2019.03.015.", "ArticleIdList": ["10.1016/j.drudis.2019.03.015", "30890362"]}, {"Citation": "Norinder U., Bergstr\u00f6m C.A. Prediction of ADMET properties. ChemMedChem Chem. Enabling Drug Discov. 2006;1:920\u2013937.", "ArticleIdList": ["16952133"]}, {"Citation": "Dearden J.C. In silico prediction of drug toxicity. J. Comput. Aided Mol. Des. 2003;17:119\u2013127. doi: 10.1023/A:1025361621494.", "ArticleIdList": ["10.1023/A:1025361621494", "13677480"]}, {"Citation": "Idakwo G., Luttrell J., Chen M., Hong H., Zhou Z., Gong P., Zhang C. A review on machine learning methods for in silico toxicity prediction. J. Environ. Sci. Health Part C. 2018;36:169\u2013191. doi: 10.1080/10590501.2018.1537118.", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Kruhlak N., Benz R., Zhou H., Colatsky T. (Q) SAR modeling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012;91:529\u2013534. doi: 10.1038/clpt.2011.300.", "ArticleIdList": ["10.1038/clpt.2011.300", "22258468"]}, {"Citation": "Ran F., Li W., Qin Y., Yu T., Liu Z., Zhou M., Liu C., Qiao T., Li X., Yousef R.G. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxidative Med. Cell. Longev. 2021;2021:8321400. doi: 10.1155/2021/8321400.", "ArticleIdList": ["10.1155/2021/8321400", "PMC8568530", "34745424"]}, {"Citation": "El-Zahabi M.A., Sakr H., El-Adl K., Zayed M., Abdelraheem A.S., Eissa S.I., Elkady H., Eissa I.H. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg. Chem. 2020;104:104218. doi: 10.1016/j.bioorg.2020.104218.", "ArticleIdList": ["10.1016/j.bioorg.2020.104218", "32932121"]}, {"Citation": "El-Adl K., El-Helby A.-G.A., Sakr H., Elwan A. [1, 2, 4] Triazolo [4, 3-a] quinoxaline and [1, 2, 4] triazolo [4, 3-a] quinoxaline-1-thiol-derived DNA intercalators: Design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations. New J. Chem. 2021;45:881\u2013897. doi: 10.1039/D0NJ02990D.", "ArticleIdList": ["10.1039/D0NJ02990D"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "9", "Day": "23"}, {"Year": "2022", "Month": "10", "Day": "28"}, {"Year": "2022", "Month": "10", "Day": "31"}, {"Year": "2022", "Month": "11", "Day": "26", "Hour": "1", "Minute": "26"}, {"Year": "2022", "Month": "11", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "11", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["36431818", "PMC9697799", "10.3390/molecules27227719", "molecules27227719"]}}], "PubmedBookArticle": []}